Waldencast has sold Obagi Medical — the 38-year-old professional skincare brand founded by dermatologist Dr. Zein Obagi — to European private equity firm Bridgepoint Group for $460 million. The deal is one of the more significant transactions in the clinical skincare space in recent memory, and it signals something broader: institutional investors are increasingly convinced that the gap between the dermatologist's office and the beauty aisle is closing fast.
Obagi Medical's $460M Sale Signals Private Equity's Appetite for Clinical Skincare
Waldencast has offloaded Obagi Medical to private equity firm Bridgepoint for $460 million, underscoring how seriously institutional money is now chasing the intersection of dermatology and beauty. Here's what the deal means for the brand and the broader skincare market.
This is a Pro article
Subscribe to read the full article and support independent AI journalism.